Superworth

Alnylam Pharmaceuticals ALNY

Biotechnology, Healthcare
$158.50
+0.32%
Market cap
$21.2B
PE
26.7×
Forward PE
18.9×
10y median 61.6×
Price to sales
4.4×
EV/EBIT
19.2×
Revenue, 12 months
$4.8B
+95% on a year ago
Net margin
16.8%
Free cash flow yield
3.7%

Alnylam Pharmaceuticals trades at 26.7× trailing earnings. Revenue was $4.8B over the last twelve months, up 95% on a year earlier with a 17% net margin.

Charts

Financials

Income statement for ALNY, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$750.5M+184%$439.7M+31%$494.3M+55%$659.8M+107%$500.9M−33%$593.2M+35%$594.2M+20%$773.7M+17%$1.2B+149%$1.1B+85%$1.2B+96%$1.3B+67%
Cost of revenue$84.3M+105%$85.9M+68%$66M+20%$68.7M−20%$85.9M+2%$102.8M+20%$71M+8%$143M+108%$200.2M+133%$267.7M+160%$211.1M+197%$298.5M+109%
Gross profit$666.2M+199%$353.9M+25%$428.4M+62%$591.2M+153%$415M−38%$490.3M+39%$523.1M+22%$630.7M+7%$1B+153%$829.3M+69%$956.1M+83%$992.5M+57%
R&D$253.2M+3%$272.1M+4%$261M+13%$294.1M+18%$270.9M+7%$300.2M+10%$265.1M+2%$323.6M+10%$358.8M+32%$372.2M+24%$364.9M+38%$413.1M+28%
SG&A$199.2M−16%$198.1M−6%$210.8M+15%$248.4M+16%$221M+11%$295.3M+49%$239.9M+14%$323.3M+30%$322.1M+46%$325.4M+10%$322.6M+34%$347.9M+8%
$213.9M−$116.4M−38%−$43.4M−71%$48.6M−$76.9M−$105.2M−10%$18.1M−$16.2M$368M$131.7M$268.6M+1386%$231.4M
Interest expense$30.9M−25%$31.3M+5%$35.3M+22%$33.3M+11%$34.4M+11%$39M+24%$58.3M+65%$61.5M+85%$44.4M+29%$129.3M+232%$69.3M+19%$82.1M+34%
Pre-tax income$150.7M−$137.7M−34%−$63.6M−63%−$11.2M−96%−$108.7M−$194M+41%−$2.4M−96%−$41.3M+270%$239M$161.1M$221.7M$177.8M
$3M$183K−61%$2.3M+35%$5.7M+215%$2.9M−3%−$110.2M$15.9M+576%$30.9M+440%−$12.1M−$25.3M−77%$15.7M−1%$13.3M−57%
Net income$147.8M−$137.9M−34%−$65.9M−62%−$16.9M−94%−$111.6M−$83.8M−39%−$18.3M−72%−$72.2M+328%$251.1M$186.4M$206M$164.5M
$1.15−$1.10−35%−$0.52−63%−$0.13−94%−$0.87−$0.65−41%−$0.14−73%−$0.55+323%$1.84$1.37$1.51$1.21
131.3M+8%125.6M+2%126.1M+2%126.7M+2%128.6M−2%129.1M+3%129.7M+3%130.6M+3%137.3M+7%136.3M+6%138.2M+7%138.3M+6%

Gross profit: 32 periods, Q3 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 7 periods, Q4 FY09 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: .

QuarterRevenueRangeEPSRangeAnalysts
Q3 FY26$1.4B$1.4B to $1.5B$1.66$1.53 to $1.8010
Q4 FY26$1.5B$1.4B to $1.6B$1.72$1.33 to $2.1210
Q1 FY27$1.5B$1.5B to $1.7B$1.67$1.54 to $1.766
Q2 FY27$1.7B$1.6B to $1.8B$1.69$1.56 to $1.912
Q3 FY27$1.7B$1.6B to $1.9B$1.95$1.80 to $2.212
Q4 FY27$1.8B$1.7B to $2B$2.51$2.32 to $2.842
Q1 FY28$1.7B$1.6B to $1.9B$2.38$2.20 to $2.695
Q2 FY28$1.8B$1.7B to $2B$2.34$2.15 to $2.645

Peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
ALNYAlnylam Pharmaceuticals$21.2B26.7×68.2×18.9×4.4×+95%16.8%
INCYIncyte$24.3B15.3×36.5×51.3×4.2×+27%27.7%
UTHRUnited Therapeutics$25.9B21.6×14.2×22.6×8.2×+2%41.6%
EXELExelixis$17.4B22.1×22.7×n/m7.1×+9%35.3%
NBIXNeurocrine Biosciences$14.8B21.3×42.6×n/m4.4×+34%20.9%
HALOHalozyme Therapeutics$14.6B38.5×21.3×n/m8.8×+41%24.9%
TECHBIO-TECHNE$11.4B63.2×62.0×n/m9.4×−0%15.0%
ONCBeOne Medicines$40.2B63.2×67.6×45.0×6.6×+34%10.7%
RGENRepligen$9.8B237×123×n/m12.4×+16%5.3%
KRYSKrystal Biotech$8.8B37.1×42.5×n/m19.9×+23%54.8%
REGNRegeneron Pharmaceuticals$100B24.0×19.7×15.1×6.4×+9%27.9%
Peer median$16.1B30.5×39.5×33.8×7.7×+20%26.3%

Investors who own it

Investors we follow who held Alnylam Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.

More on Alnylam Pharmaceuticals

Each number over time

Where it ranks

Its groups

About

Industry
Biotechnology
Sector
Healthcare

Valuation data, not investment advice. Prices as of .